--- title: To Compare the Analgesic Effects of Different Nerve Block Analgesia Methods in Thoracoscopic Surgery nct_id: NCT06598852 overall_status: RECRUITING phase: NA sponsor: The First Hospital of Qinhuangdao study_type: INTERVENTIONAL primary_condition: Postoperative Analgesia countries: China canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06598852.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06598852" ct_last_update_post_date: 2024-12-02 last_seen_at: "2026-05-12T06:43:02.184Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # To Compare the Analgesic Effects of Different Nerve Block Analgesia Methods in Thoracoscopic Surgery **Official Title:** Comparison of Analgesic Effects of Ultrasound-guided Thoracic Paravertebral Block, Erector Spinae Muscle Block, Thoracic Paravertebral Block Combined with Erector Spinae Muscle Block, and Intercostal Nerve Block in Thoracoscopic Surgery **NCT ID:** [NCT06598852](https://clinicaltrials.gov/study/NCT06598852) ## Key Facts - **Status:** RECRUITING - **Phase:** NA - **Study Type:** INTERVENTIONAL - **Target Enrollment:** 120 - **Lead Sponsor:** The First Hospital of Qinhuangdao - **Conditions:** Postoperative Analgesia - **Start Date:** 2024-09-15 - **Completion Date:** 2025-01-20 - **CT.gov Last Update:** 2024-12-02 ## Brief Summary Comparison of analgesic effects of ultrasound-guided thoracic paravertebral block, erector spinae muscle block, thoracic paravertebral block combined with erector spinae muscle block, and intercostal nerve block in thoracoscopic surgery ## Detailed Description 120 patients undergoing elective thoracoscopic surgery were randomly divided into ESPB group (E group, n=30), TPVB group (T group, n=30), ESPB combine with TPVB group (ET group, n=30), ICNB group (I group, n=30). Patients in ESPB group underwent erector spinal block under ultrasound after anesthesia induction; Patients in TPVB group received thoracic paravertebral nerve block after anesthesia induction; Patients in ESPB group combined with TPVB group received thoracic paravertebral nerve block combined with erectoralis muscle block after anesthesia induction; Patients in INB group received intraoperative intercostal nerve block by the operator. All groups of patients received postoperative controlled intravenous analgesia (PCIA). Visual analogue scale (VAS) was used to evaluate the degree of pain 1h (T1), 24h (T2) and 48h (T3) after surgery. The mean arterial pressure (MAP), heart rate at T1-T3 were recorded, as well as the number of effective analgesic pump compression, the amount of sufentanil and the number of relief analgesia within 48h after surgery. The occurrence of postoperative adverse reactions such as nausea, vomiting, dizziness, retention time of thoracic drainage tube, postoperative hospital stay and postoperative pulmonary complications (pneumonia, atelectasis, pleural effusion, respiratory failure, etc.) were recorded. ## Eligibility - **Minimum age:** 18 Years - **Maximum age:** 70 Years - **Sex:** ALL - **Healthy Volunteers:** No ``` Inclusion Criteria: * (1) American Society of Anesthesiologists (ASA) Grade I-II; (2) Age: 18-70 years old (3) double-hole thoracic surgery was performed; (4) Agree to participate in this study and sign the informed consent. Exclusion Criteria: * (1) People who are allergic to anesthetics used in this study; (2) Patients with coagulation disorders (3) patients with severe heart disease, liver or renal insufficiency; (4) have a history of chronic pain or chronic opioid users (5) have a co-existing mental illness and are not fully capable of cooperating ``` ## Arms - **TPVB group** (EXPERIMENTAL) — Ultrasound-guided thoracic paravertebral nerve block was used for postoperative analgesia after thoracic surgery - **ESPB group** (EXPERIMENTAL) — Ultrasound-guided erector spinae muscle block was used for postoperative analgesia after thoracic surgery - **TPVB combined ESPB group** (EXPERIMENTAL) — Ultrasound-guided thoracic paravertebral nerve block combined with erector spinae muscle block was used for postoperative analgesia after thoracic surgery - **ICNB group** (EXPERIMENTAL) — Intercostal nerve block was used for postoperative analgesia after thoracic surgery ## Interventions - **TPVB group** (OTHER) — Patients undergoing thoracoscopic surgery underwent general anesthesia and patients in TPVB Group received thoracic paravertebral nerve block with 0.33% ropivacaine 30ml under ultrasound guidance after anesthesia induction for postoperative analgesia. - **ESPB group** (OTHER) — Patients undergoing thoracoscopic surgery underwent general anesthesia and patients in ESPB Group received erector spinae muscle block with 0.33% ropivacaine 30ml under ultrasound guidance after anesthesia induction for postoperative analgesia. - **TPVB combined ESPB group** (OTHER) — Patients undergoing thoracoscopic surgery underwent general anesthesia and patients in TPVB combined ESPB group received thoracic paravertebral block combined with erector spinae muscle block with 0.33% ropivacaine 30ml under ultrasound guidance after anesthesia induction for postoperative analgesia. - **ICNB group** (OTHER) — Patients undergoing thoracoscopic surgery underwent general anesthesia and patients in ICNB Group received intercostal nerve block for postoperative analgesia. ## Primary Outcomes - **Postoperative pain score** _(time frame: 48 hours after surgery)_ — Visual analogue scale (VAS) was used to evaluate the degree of pain 1h (T1), 24h (T2) and 48h (T3) after surgery, the number of effective analgesic pump compressions and the number of remedial analgesia within 48h after surgery. ## Secondary Outcomes - **Incidence of postoperative complications** _(time frame: 48 hours after surgery)_ ## Locations (1) - First hospital of Qinhuangdao, Qinhuangdao, Hebei, China — _RECRUITING_ ## Recent Field Changes (last 30 days) - `status.overallStatus` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.phases` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.maxAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `outcomes.secondary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.first hospital of qinhuangdao|qinhuangdao|hebei|china` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT06598852.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT06598852* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*